<DOC>
	<DOCNO>NCT01601119</DOCNO>
	<brief_summary>The objective establish impact current disease modifying therapy ( DMTs ) associate support service Patient Reported Experience Measures Patient Reported Outcomes relation treatment management Relapsing Multiple Sclerosis United Kingdom ( UK ) .</brief_summary>
	<brief_title>Impact Disease Modifying Therapies ( DMTs ) Associated Support Services Relapsing Multiple Sclerosis ( RMS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Relapsing Multiple Sclerosis patient age 18 year . Naive previous DMT therapy yet start treatment disease modify therapy . Participating MSrelated clinical trial . Unwilling provide electronic online consent . Any disability may impair able complete online questionnaire . Do regular access Internet . Unable complete baseline questionnaire receive first DMT injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Patient report outcome</keyword>
	<keyword>Patient report experience</keyword>
</DOC>